Evinacumab
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia
Conditions
Homozygous Familial Hypercholesterolemia
Trial Timeline
Feb 21, 2023 → Mar 18, 2025
NCT ID
NCT05611528About Evinacumab
Evinacumab is a phase 3 stage product being developed by Ultragenyx Pharmaceutical for Homozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05611528. Target conditions include Homozygous Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05611528 | Phase 3 | Completed |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia